Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) saw an upside of 1.30% to close Monday at $18.72 after adding $0.24 on the day. The 5-day average trading volume is 1,181,920 shares of the company’s common stock. It has gained $18.97 in the past week and touched a new high 1 time within the past 5 days. An average of 962,345 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,158,626.
AMLX’s 1-month performance is -13.85% or -$3.13 on its low of $17.80 reached on 09/25/23. The company’s shares have touched a 52-week low of $18.03 and high of $41.93, with the stock’s rally to the 52-week high happening on 01/30/23. YTD, AMLX has lost -49.34% or -$18.23 and has reached a new high 6 times. However, the current price is down -55.35% from the 52-week high price.
Insider Transactions
AMLX stock investors last saw insider trading activity on Aug 15.Mazzariello Gina (Chief Legal Officer) most recently sold 6,164 shares at $20.88 per share on Aug 15. This transaction cost the insider $128,686. Chief Financial Officer, FRATES JAMES M, sold 32,500 shares at a price of $26.94 on May 16. Then, on May 15, Chief Medical Officer Yeramian Patrick D sold 11,965 shares at a price of $29.03 per share. This transaction amounted to $347,358.
Valuation Metrics
AMLX stock has a beta of -0.77. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 6.57 while the price-to-book (PB) in the most recent quarter is 3.26.
Amylyx Pharmaceuticals Inc’s quick ratio for the period ended June 29 was 6.28, with the current ratio over the same period at 6.67. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.01, while the total debt to equity was 0.01. In terms of profitability, the gross margin trailing 12 months is 92.34%. The trailing 12-month EBITDA margin is -903.53% while for the period ending June 29, Amylyx Pharmaceuticals Inc’s operating margin was -42.28%. The firm’s gross profit as reported stood at $19.24 million against revenue of $22.23 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 344.99% to $22.07 million, while revenue of $1.57 million was 92.89% off the previous quarter. Analysts expected AMLX to announce $0.1 per share in earnings in its latest quarter, but it posted $0.31, representing a 210.00% surprise. EBITDA for the quarter stood at more than $18.5 million. AMLX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 67.22 million, with total debt at $5.29 million. Shareholders hold equity totaling $67.38 million.
Let’s look briefly at Amylyx Pharmaceuticals Inc (AMLX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 25 September was 35.61% to suggest the stock is trending Neutral, with historical volatility in this time period at 37.24%.
The stock’s 5-day moving average is $18.55, reflecting a +0.11% or $0.02 change from its current price. AMLX is currently trading -14.32% above its 20-day SMA, -32.66% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -17.39% and SMA200 by-49.66%.
Stochastic %K and %D was 12.98% and 7.47% and the average true range (ATR) pointed at 0.69. The RSI (14) points at 35.91%, while the 14-day stochastic is at 26.44% with the period’s ATR at 0.73. The stock’s 9-day MACD Oscillator is pointing at -0.57 and -1.18 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), Goldman upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for AMLX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate AMLX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 5 have offered a “buy” rating.
What is AMLX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $45.00 and a high of $50.00, with their median price target at $47.00. Looking at these predictions, the average price target given by analysts is for Amylyx Pharmaceuticals Inc (AMLX) stock is $47.40.
